In Study 2 of the pivotal Phase 3 UP-AA clinical program, upadacitinib (RINVOQ®) achieved the primary endpoint, demonstrating that 44.6% and 54.3% of ...

The boy has a long road to recovery, as he requires more surgeries to repair his still-damaged body. At one point, he cried and yelled, refusing more operations; at another, he comforted his ...